ArticleJournal of transplantation2025
Effectiveness and Safety of Reduced Thymoglobulin Dosing in Low-Risk Kidney Transplant Recipients.
Article in Journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Safety of Reduced Thymoglobulin Dosing in Low-Risk Kidney Transplant Recipients.Journal of transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thymoglobulin, a lymphocyte-depleting agent, is widely used for induction immunosuppression in kidney transplantation. Despite guideline support, there is no standardized dosing recommendation, resulting in variability across centers. In April 2022, our institution reduced its institutional practice thymoglobulin dose from 4.5 to 3 mg/kg for low-risk kidney transplant recipients. This study aimed to evaluate the noninferiority of the reduced dose compared to the prior regimen in terms of effectiveness and safety. Methods: This single-center retrospective noninferiority cohort study of low-risk kidney transplant recipients was conducted from April 2020 to April 2024. Patients received either 3 or 4.5 mg/kg of thymoglobulin. The primary outcome was a composite of biopsy-proven or suspected acute rejection, graft loss, or death within 6 months posttransplant. Secondary outcomes included leukopenia, thrombocytopenia, infections, delayed graft function, eGFR, malignancies, and hospital length of stay. Results: A total of 196 patients were included (116 in 4.5 mg/kg; 80 in 3 mg/kg). The primary outcome occurred in 11% and 3% of patients, respectively (risk difference -8.7%, 95% CI -15.4 to -2.0; Conclusion: A 3 mg/kg thymoglobulin dose is noninferior to 4.5 mg/kg and is associated with improved safety in low-risk kidney transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.